ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

Q1 2023 ACADIA Pharmaceuticals Inc Earnings Call Transcript

May 08, 2023 / 08:30PM GMT
Release Date Price: $21.55 (-1.73%)
Operator

Good day, ladies and gentlemen. Thank you for standing by. Welcome to ACADIA Pharmaceuticals First Quarter 2023 Financial Results Conference Call. My name is Corey, and I will be your coordinator for today.(Operator Instructions)

Please be advised today's conference call is being recorded. I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed.

Mark C. Johnson
ACADIA Pharmaceuticals Inc. - VP of IR

Thank you. Good afternoon, and thank you for joining us on today's call to discuss ACADIA's first quarter 2023 financial results. Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer, who will provide an overview of our performance and review of our business; Brendan Teehan, our Chief Operating Officer, Head of Commercial, will provide updates on our recent launch of DAYBUE for the treatment of Rett syndrome followed by commercial updates on our NUPLAZID franchise; Doug Williamson, our Head of R&D, will provide an update of our pipeline programs, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot